F-star Therapeutics (NASDAQ:FSTX) Stock Rating Lowered by LADENBURG THALM/SH SH

F-star Therapeutics (NASDAQ:FSTXGet Rating) was downgraded by equities research analysts at LADENBURG THALM/SH SH from a “buy” rating to a “neutral” rating in a report released on Thursday, The Fly reports.

Several other research analysts have also recently weighed in on FSTX. William Blair cut shares of F-star Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday. HC Wainwright assumed coverage on shares of F-star Therapeutics in a report on Tuesday, May 17th. They set a “buy” rating and a $35.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.50.

F-star Therapeutics stock traded up $2.26 during trading hours on Thursday, hitting $6.24. The stock had a trading volume of 292,580 shares, compared to its average volume of 136,191. The company has a quick ratio of 6.11, a current ratio of 6.11 and a debt-to-equity ratio of 0.14. The stock’s 50-day moving average price is $2.98 and its 200-day moving average price is $3.63. F-star Therapeutics has a 12-month low of $2.07 and a 12-month high of $9.52. The stock has a market capitalization of $134.53 million, a P/E ratio of -4.07 and a beta of 1.84.

F-star Therapeutics (NASDAQ:FSTXGet Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.06. The company had revenue of $2.55 million for the quarter, compared to analysts’ expectations of $2.30 million. On average, research analysts expect that F-star Therapeutics will post -2.35 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. grew its position in F-star Therapeutics by 1.6% during the first quarter. BlackRock Inc. now owns 295,947 shares of the company’s stock valued at $1,050,000 after buying an additional 4,776 shares during the period. State Street Corp boosted its position in shares of F-star Therapeutics by 15.6% in the first quarter. State Street Corp now owns 53,150 shares of the company’s stock worth $189,000 after purchasing an additional 7,180 shares during the period. JPMorgan Chase & Co. boosted its position in shares of F-star Therapeutics by 152.7% in the first quarter. JPMorgan Chase & Co. now owns 21,335 shares of the company’s stock worth $76,000 after purchasing an additional 12,891 shares during the period. Envestnet Asset Management Inc. bought a new position in shares of F-star Therapeutics in the first quarter worth approximately $48,000. Finally, Geode Capital Management LLC boosted its position in shares of F-star Therapeutics by 11.6% in the third quarter. Geode Capital Management LLC now owns 145,431 shares of the company’s stock worth $1,064,000 after purchasing an additional 15,152 shares during the period. Institutional investors own 51.67% of the company’s stock.

F-star Therapeutics Company Profile (Get Rating)

F-star Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.

Recommended Stories

The Fly logo

Analyst Recommendations for F-star Therapeutics (NASDAQ:FSTX)

Receive News & Ratings for F-star Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for F-star Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.